Innovation Ed
SWISS-APERO: One-year outcomes after Amulet or Watchman/FLX device for percutaneous LAA closure
Video by PCR via YouTube
Go to Source
Alessandro Sticchi interviews Roberto Galea about the pre-specified analysis of the SWISS-APERO randomized clinical trial which he presented during the TCT Congress 2023 in San Francisco.
Among patients undergoing clinically indicated #LAAC and in whom LAA anatomy was deemed suitable for both devices, rates of patency and device-related thrombus at 13-month cardiac computed tomography angiography, as well as clinical outcomes, were similar between the two groups.
Read more news from #TCT2023 here:
https://www.pcronline.com/News/Whats-new-on-PCRonline/2023/TCT/PCRonline-at-TCT-2023